ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Kisspeptin suppression under TRT: Can it affect mood and libido?
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Cataceous" data-source="post: 249702" data-attributes="member: 38109"><p>I agree there are unknowns in all of these treatments. I don't have a sense about which carries greater risk. Hopefully all of the risks are small in an absolute sense.</p><p></p><p>The background for others:</p><p>Regarding SERMs, it bothers me that they are—mostly—not endogenous and that there's limited characterization of the effects they have on all the different estrogen receptors in our bodies. We can get the desired effect, with the hypothalamus and pituitary feeling estrogen-deprived. But SERMs are not that purely selective, as we see with enclomiphene's suppression of IGF-1, which implies liver activity. This opens the door to other suppression we're unaware of, which might bite us in the long run.</p><p></p><p>The testosterone-based treatments use bioidentical molecules, but they can cause HPTA shutdown, reducing or eliminating natural production of kisspeptin, GnRH, LH and FSH. I continue to wonder out loud about the possible negative consequences of this, given that these hormones have effects that are distinct from their roles in the HPTA.</p></blockquote><p></p>
[QUOTE="Cataceous, post: 249702, member: 38109"] I agree there are unknowns in all of these treatments. I don't have a sense about which carries greater risk. Hopefully all of the risks are small in an absolute sense. The background for others: Regarding SERMs, it bothers me that they are—mostly—not endogenous and that there's limited characterization of the effects they have on all the different estrogen receptors in our bodies. We can get the desired effect, with the hypothalamus and pituitary feeling estrogen-deprived. But SERMs are not that purely selective, as we see with enclomiphene's suppression of IGF-1, which implies liver activity. This opens the door to other suppression we're unaware of, which might bite us in the long run. The testosterone-based treatments use bioidentical molecules, but they can cause HPTA shutdown, reducing or eliminating natural production of kisspeptin, GnRH, LH and FSH. I continue to wonder out loud about the possible negative consequences of this, given that these hormones have effects that are distinct from their roles in the HPTA. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Kisspeptin suppression under TRT: Can it affect mood and libido?
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top